“IDeate-Prostate01 marks the initiation of the third pivotal trial in the ifinatamab deruxtecan development program and reinforces our commitment to addressing critical unmet needs for patients ...

IDeate-Prostate01 is a multicenter, open-label, randomized phase 3 trial evaluating the safety and efficacy of ifinatamab deruxtecan (12 mg/kg) versus docetaxel (75 mg/m 2) plus corticosteroid in ...

Vidhya Subramanian redefines classical dance with 'Damaru', showcasing tradition and innovation in a changing world.

In these gaps, we have discovered that systems don’t quite align, and people end up navigating workarounds instead of actual ...

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer Jun. 18, 2025 7:00 AM ET Merck & Co., Inc. (MRK), DSKYF ...

Priyanka Jain, CEO of Evvy, wants an employee who can not only strategize, but also execute. At a startup, she says, ...

AI can transform relationships throughout the client lifecycle, allowing humans to focus on deeper connections and sustained ...

The final day of the summit had a short program, including panel discussions about integrating AI into workflows, measuring the success of AI tools and AI governance, privacy and ...

BASKING RIDGE, N.J. & RAHWAY, N.J.-- (BUSINESS WIRE)--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab ...

BASKING RIDGE, N.J. & RAHWAY, N.J., June 18, 2025--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab ...

BASKING RIDGE, N.J. & RAHWAY, N.J., June 18, 2025--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 clinical trial to evaluate the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with ...